Ruxolitinib for Early Lung Dysfunction After Hematopoietic Stem Cell Transplant

NCT04908735 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

7

Enrollment

OTHER

Sponsor class

Stopped Study closed due to slow enrollment.

Conditions

Hematopoietic Stem Cell Transplant (HSCT)
Bronchiolitis Obliterans (BO)

Interventions

DRUG: Ruxolitinib

Sponsor

Children's Hospital Medical Center, Cincinnati